The diagnostic criteria used to identify patients suffering from
polycystic ovary syndrome remain controversial. The present prospective
longitudinal follow-up study was designed to identify whether certain
criteria assessed during standardized initial screening could predict the
response to ovulation induction with clomiphene citrate (CC) in 201
patients presenting with oligomenorrhea or amenorrhea and infertility.
Serum FSH levels were within the normal range (1-10 IU/L), and all
patients underwent spontaneous or progestin-induced withdrawal bleeding.
Initial CC doses were 50 mg daily for 5 days starting on cycle day 3. In
the case of an absent response, doses were increased to 100 and 150 mg
daily in subsequent cycles. First ovulation with CC was used as the end
point. After a complete follow-up (in the case of a nonresponse, at least
3 treatment cycles with daily CC doses up to 150 mg), 156 patients (78%)
ovulated. The free androgen index (FAI = testosterone/sex hormone-binding
globulin ratio), body mass index (BMI), cycle history (oligomenorrhea vs.
amenorrhea), serum androgen (testosterone and/or androstenedione) levels,
and mean ovarian volume assessed by transvaginal sonography were all
significantly different (P < 0.01) in responders from those in
nonresponders. FAI was chosen to be the best predictor in univariate
analysis. The area under the receiver operating characteristics curve in a
multivariate prediction model including FAI, BMI, cycle history, and mean
ovarian volume was 0.82. Patients whose ovaries are less likely to respond
to stimulation by FSH due to CC treatment can be predicted on the basis of
initial screening characteristics, such as FAI, BMI, cycle history
(oligomenorrhea or amenorrhea), and mean ovarian volume. These
observations may add to ongoing discussion regarding etiological factors
involved in ovarian dysfunction in these patients and classification of
normogonadotropic anovulatory infertile women